

primary studies - published RCT

## **A double blind lipase for lipase comparison of a high lipase and standard pancreatic enzyme preparation in cystic fibrosis.**

**Code:** PM7683190

**Year:** 1993 **Date:** 1998

**Author:** Bowler IM

### **Study design (if review, criteria of inclusion for studies)**

Parallel design. Randomisation table used.

### **Participants**

Once daily: n = 12 (8 male); age range 5.6 - 19.3 years. 22 participants with diagnosis of CF. Thrice daily: n = 10 (6 male); age range 7.4 - 17.2 years. Pulmonary exacerbation defined.

### **Interventions**

14 days of treatment. Once-daily dosing (15 mg/kg/day) versus thrice-daily dosing (15 mg/kg/day) of tobramycin. Combination therapy with ceftazidime (200 mg/kg/day).

### **Outcome measures**

Weight/Height %. Lung function: FEV1 and FVC. Ototoxicity. Nephrotoxicity: creatinine clearance; lysozymuria; B2-microglobulinuria; 24 hour proteinuria.

### **Main results**

Variables improving (p

### **Authors' conclusions**

Once daily tobramycin combined with three injections of ceftazidime is safe and effective for the treatment of pseudomonas exacerbations in cystic fibrosis patients.

<http://dx.doi.org/10.1136/adc.68.2.227>

### **See also**

Arch Dis Child. 1993 Feb;68(2):227-30.

### **Keywords**

Adolescent; Adult; Anti-Bacterial Agents; Bacterial Infections; Ceftazidime; Cephalosporins; Child; Drug Administration Schedule; Infection; Intravenous; pharmacological\_intervention; Pseudomonas aeruginosa; Pseudomonas; Respiratory Tract Diseases; Respiratory Tract Infections; Tobramycin; Exacerbation; Aminoglycosides;